Work

Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease.

Year: 2011

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2011.29.7_suppl.127

Authors: D. C. Smith, M. R. Smith, E. J. Small, C. Sweeney, R. Kurzrock, M. S. Gordon, N. J. Vogelzang, C. Scheffold, M. D. Ballinger, M. Hussain

Institutions: The University of Texas MD Anderson Cancer Center, Exelixis (United States), University of California, San Francisco, University of Michigan, Massachusetts General Hospital, Dana-Farber Cancer Institute, Comprehensive Cancer Centers of Nevada, U-M Rogel Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2560459408

Cites:

Cited by: 23

Related to: 10